MiamiNets is #ASCO24 ready.

Let’s catch up over coffee!! ☕️

Also please checkout our ongoing work on Multi Center Randomized Phase II ETCTN 10558 Triapine+Lu-177 dotatate vs Lu-177-dotatate in GEPNETs. Trial enrolling at brisk pace.

Also checkout splendid work from our ⭐️

Notes✅
Patient Calls✅
Research Meeting with my awesome resident Brandon Rose, MD, MPH ✅
Monthly PI calls with external sites on our IITs ETCTN 10388,10450✅
Now on to best part. Hanging with fam. #WorkLife Balance #MiamiLove Sylvester Comprehensive Cancer Center

Thrilled to visit USC & meet the hardworking team led by Dr Robert Hsu (Robert Hsu MD) while at #TTLC24

🚀🧬 team science for NUT carcinoma trials through CTEP ETCTN

After consenting 1st patient on ETCTN 10450 exp cohort last week, we consented a pt on Paltusotine Study today. Tomorrow we are consenting two pts on #PRRT study. So gratifying to be part of clinical research 🙏 to patients. ➡️1st Miami NET patient conference brochures are here🦓

Dr Zeynep Eroglu Moffitt Cancer Center presents study of dab/tram +/- Navitoclax in BRAF mutated #melanoma . Interesting biological rationale. Good use of ETCTN mechanism to explore combo. Some unique stats (not designed to directly compare cohorts) given small N. #ASCO23 1/

Join us tomorrow (April 9, 2024 at 3:35 PM - 3:45 PM PT) for an update on #ETCTN (10217) #clinicaltrial , which assessed the combo of Copa (pan-PI3K inhibitor) and Ola (PARP inhibitor) in #solidtumors harboring mutations in PI3K/AKT or DDR pathways. #AACR24 buff.ly/4alinY5

New #ETCTN (10637) #clinicaltrial is available for patients diagnosed with relapsed hairy cell leukemia ( #HCL ). This trial is led by Dr. Robert Kreitman (PI) of NCI Center for Cancer Research. Learn more about this #leukemia research today: buff.ly/3VbSchp

Got approval on last day of OEWG deadline. Triapine/PRRT RCT is now active in US and Canada. All ETCTN/EDDOP sites are welcome to open ETCTN 10558. Co-leading this study with ⁦mentor ⁦Lowell Anthony⁩
Fantastic joint effort by ⁦Markey Cancer Center⁩ ⁦Sylvester Comprehensive Cancer Center⁩

Happy to share an important career milestone. Will be leading ETCTN 10558, RCT (Triapine/PRRT Vs PRRT in NETs). Our journey from lab (2018) to successful completion of Phase 1 ETCTN 10388 (2022) was tiring but every bit inspiring and rewarding. 🙏to pts, mentors and colleagues.

This was a really fun #collaboration which started when Joost reached out to me about samples from the ETCTN/CTEP 10026 study. 📩

Joost was interested to see whether T cell networks he had seen in #pediatric #AML could also be found in adults. ⁉️
/2

x.com/livius_tacitus…

#ETCTN (10577) is a new #clinicaltrial for patients with #solidtumors that have spread from where they first started (primary), to nearby tissue, lymph nodes, or distant parts of the body (advanced), or other places in the body (metastatic). ➡️ Learn more: buff.ly/4cWWgce

‼️ New #NCICTEP #cholangiocarcinoma #clinicaltrial activation: ( #ETCTN 10608), “Durvalumab with Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery”, led by Dr. Hop S. Tran Cao of MD Anderson Cancer Center. buff.ly/3Ti92Kv #BileDuctCancer

🆕 #ETCTN (10596): “Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment for Newly Diagnosed Patients With Acute Myeloid #Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene”, led by Dr. Alice Mims of The James buff.ly/4bQ6dI0

The ETCTN/CTEP 9204 study was first to demonstrate that ipilimumab could induce long-term remissions in leukemia cutis post-HSCT.

Together with Pavan Bachireddy we worked out the details at a cellular level using several orthogonal approaches.
pubmed.ncbi.nlm.nih.gov/33720354/
Blood Journal /5

Intriguing data from LuParp study. Complements our COMRADE randomized phase 2 of radium +/- olaparib currently accruing patient through ETCTN. Home stretch! #ASCO2023 ⁦⁦UC San Diego Health Moores Cancer Center⁩

‼️ Coming to #AACR24 THIS Tuesday, April 9. Check it out ➡️ #ETCTN #clinicaltrial (9455) update…an open-label, two-part, phase II, single-arm, multicenter study for patients with triple-negative breast cancer ( #TNBC ). Vishnu Prasath, MD, MS #cancerresearch buff.ly/3VTWLxw

#Sarcomas are rare types of #cancer that begin in bone or in the soft tissues of the body. See this #AACR24 abstract for results from #ETCTN phase 2 #clinicaltrial , of #atezolizumab (atezo), in patients (pts) with advanced #sarcoma cancers . (NCI 10398). buff.ly/3xthFK5

Love my NETs colleagues who are always working in collaboration to help advance science!!

ETCTN 10450 tested Peposertib a novel DNA PKi in combination with Lutathera in NET patients. It was a joint effort of Markey Cancer Center Sylvester Comprehensive Cancer Center Clinical Trials Office, Huntsman Cancer Institute City of Hope and OSU
The first

Bittersweet to leave wonderful Markey Cancer Center family. Excited to start venture at University of Miami under guidance of Stephen D. Nimer, MD gilberto lopes Peter Hosein, MD Will be Leading NETs and RPT Drug Dev. Setting up NET lab and excited to cont work on ETCTN 10388, 10450, 10558 and NetRetreat. 🦓☢️💉💊

ENROLLING: #ETCTN (10273) is a #clinicaltrial for patients diagnosed with acute myeloid leukemia ( #AML ) that has come back (relapsed) or does not respond to treatment (refractory). See more about this #cancerresearch (PI is Dr. Brian Jonas of UC Davis Comprehensive Cancer Cent). buff.ly/3MCPBbF